[1] Schwartz WB, Bennett W, Curelop S, et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. 1957[J]. J Am Soc Nephrol, 2001, 12(12):2860-2870.
[2] Gitelman SE, Feldman BJ, Rosenthal SM. Nephrogenic syndrome of inappropriate antidiuresis:a novel disorder in water balance in pediatric patients[J]. Am J Med, 2006, 119(7 Suppl 1):S54-S58.
[3] Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors[J]. Cancer, 2008, 113(1):5-21.
[4] Gross P. Clinical management of SIADH[J]. Ther Adv Endocrinol Metab, 2012, 3(2):61-73.
[5] 覃晶, 蔡菊芬, 卢红阳. 小细胞肺癌伴发抗利尿激素异常分综合征诊治研究进展[J]. 实用医学杂志, 2014, 30(3):489-491.
[6] Iyer AV, Krasnow SH, Dufour DR, et al. Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer[J]. Clin Lung Cancer, 2003, 5(3):187-189.
[7] Wang X, Liu M, Zhang L, et al. Syndrome of inappropriate antidiuretic hormone secretion:A poor prognosis in small-cell lung cancer[J]. Arch Med Res, 2016, 47(1):19-24.
[8] Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia[J]. Eur J Endocrinol, 2014, 170(3):G1-G47.
[9] Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20):2099-2112.
[10] Elhassan EA, Schrier RW. Hyponatremia:diagnosis, complications, and management including V2 receptor antagonists[J]. Curr Opin Nephrol Hypertens, 2011, 20(2):161-168. |